382 related articles for article (PubMed ID: 19201833)
1. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
[TBL] [Abstract][Full Text] [Related]
2. CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo.
Chung Y; Kim BS; Kim YJ; Ko HJ; Ko SY; Kim DH; Kang CY
Cancer Res; 2006 Jul; 66(13):6843-50. PubMed ID: 16818662
[TBL] [Abstract][Full Text] [Related]
3. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment.
Lee JM; Seo JH; Kim YJ; Kim YS; Ko HJ; Kang CY
Int J Cancer; 2012 Aug; 131(3):741-51. PubMed ID: 21898392
[TBL] [Abstract][Full Text] [Related]
4. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
[TBL] [Abstract][Full Text] [Related]
5. DC therapy induces long-term NK reactivity to tumors via host DC.
Shimizu K; Fujii S
Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
[TBL] [Abstract][Full Text] [Related]
7. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
8. Mouse CD8
Li Z; Wu Y; Wang C; Zhang M
Cancer Immunol Immunother; 2019 Aug; 68(8):1303-1315. PubMed ID: 31278476
[TBL] [Abstract][Full Text] [Related]
9. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant.
Fernández A; Mesa C; Marigo I; Dolcetti L; Clavell M; Oliver L; Fernández LE; Bronte V
J Immunol; 2011 Jan; 186(1):264-74. PubMed ID: 21135171
[TBL] [Abstract][Full Text] [Related]
11. Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma.
Hong S; Lee H; Jung K; Lee SM; Lee SJ; Jun HJ; Kim Y; Song H; Bogen B; Choi I
Immunol Lett; 2013; 156(1-2):132-9. PubMed ID: 24148970
[TBL] [Abstract][Full Text] [Related]
12. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
Khamisabadi M; Arab S; Motamedi M; Khansari N; Moazzeni SM; Gheflati Z; Hadjati J
Iran J Immunol; 2008 Mar; 5(1):36-44. PubMed ID: 18319523
[TBL] [Abstract][Full Text] [Related]
13. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
14. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
15. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs.
Novaković S; Stegel V; Kopitar A; Ihan A; Novaković BJ
Vaccine; 2007 Nov; 25(49):8241-56. PubMed ID: 17980936
[TBL] [Abstract][Full Text] [Related]
16. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
[TBL] [Abstract][Full Text] [Related]
17. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.
Abe F; Dafferner AJ; Donkor M; Westphal SN; Scholar EM; Solheim JC; Singh RK; Hoke TA; Talmadge JE
Cancer Immunol Immunother; 2010 Jan; 59(1):47-62. PubMed ID: 19449184
[TBL] [Abstract][Full Text] [Related]
19. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.
Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy against tumor with dendritic cell sensitized by necrotic tumor tissue after microwave coagulation therapy].
Yao LC; Yang RJ
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2552-6. PubMed ID: 18067832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]